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ABSTRACT Multidrug-resistant (MDR) and extensively drug resistant (XDR) strains of
Mycobacterium tuberculosis pose major problems for global health. The GeneXpert
MTB/RIF (Xpert) assay rapidly detects resistance to rifampin (RIFr), but for detection
of the additional resistance that deﬁnes MDR-TB (MDR tuberculosis) and XDR-TB,
and for molecular epidemiology, specimen cultures and a biosafe infrastructure are
generally required. We sought to determine whether the remnants of sputa pre-
pared for the Xpert assay could be used directly to ﬁnd mutations associated with
drug resistance and to study molecular epidemiology, thus providing precise charac-
terization of MDR-TB cases in countries lacking biosafety level 3 (BSL3) facilities for
M. tuberculosis cultures. After sputa were processed and run on the Xpert instru-
ment, the leftovers of the samples prepared for the Xpert assay were used for
PCR ampliﬁcation and sequencing or for a line probe assay to detect mutations
associated with resistance to additional drugs, as well as for molecular epidemi-
ology with spoligotyping and selective mycobacterial interspersed repetitive-
unit–variable-number tandem-repeat (MIRU-VNTR) typing. Of 130 sputum sam-
ples from Gabon tested with the Xpert assay, 124 yielded interpretable results;
21 (17%) of these were determined to be RIFr. Ampliﬁcation and sequencing or a
line probe assay of the Xpert remnants conﬁrmed 18/21 samples as MDR, corre-
sponding to 12/116 (9.5%) new and 6/8 (75%) previously treated TB patients.
Spoligotyping and MIRU typing with hypervariable loci identiﬁed an MDR Beijing
strain present in ﬁve samples. We conclude that the remnants of samples pro-
cessed for the Xpert assay can be used in PCRs to ﬁnd mutations associated with
the resistance to the additional drugs that deﬁnes MDR and XDR-TB and to
study molecular epidemiology without the need for culturing or a biosafe infra-
structure.
KEYWORDS Mycobacterium tuberculosis, Libreville, Gabon, MDR-TB, molecular
epidemiology, GeneXpert, sequencing, Beijing family, drug resistance, drug
sensitivity testing, multidrug resistance
Tuberculosis (TB) is now the leading cause of death from an infectious diseaseworldwide, with an estimated 10.4 million new cases and 1.4 million deaths in 2015
(1). Of these, an estimated 480,000 new cases were multidrug-resistant TB (MDR-TB),
Received 28 December 2016 Returned for
modiﬁcation 27 February 2017 Accepted 18
April 2017
Accepted manuscript posted online 26
April 2017
Citation Alame-Emane AK, Pierre-Audigier C,
Aboumegone-Biyogo OC, Nzoghe-Mveang A,
Cadet-Daniel V, Sola C, Djoba-Siawaya JF,
Gicquel B, Takiff HE. 2017. Use of GeneXpert
remnants for drug resistance proﬁling and
molecular epidemiology of tuberculosis in
Libreville, Gabon. J Clin Microbiol 55:2105–
2115. https://doi.org/10.1128/JCM.02257-16.
Editor Geoffrey A. Land, Carter BloodCare &
Baylor University Medical Center
Copyright © 2017 Alame-Emane et al. This is
an open-access article distributed under the
terms of the Creative Commons Attribution 4.0
International license.
Address correspondence to Joël Fleury Djoba-
Siawaya, joel.djoba@gmail.com, or Brigitte
Gicquel, brigitte.gicquel@pasteur.fr.
A.K.A.-E., C.P.-A., and O.C.A.-B. contributed
equally to this article.
MYCOBACTERIOLOGY AND
AEROBIC ACTINOMYCETES
crossm
July 2017 Volume 55 Issue 7 jcm.asm.org 2105Journal of Clinical Microbiology
 o
n
 N
ovem
ber 13, 2019 at INSTITUT PASTEUR-Bibliotheque
http://jcm.asm.org/
D
ow
nloaded from
 
caused by strains resistant to at least isoniazid (INH) and rifampin (RIF). There are
effective multidrug regimens that can cure 80% of MDR-TB cases in 9 to 12 months
(2–4), but the MDR-TB cases must ﬁrst be detected (5). When an MDR strain is also
resistant to the ﬂuoroquinolones (FQ) and an injectable agent, the disease is termed
extensively drug resistant TB (XDR-TB) and is unlikely to be cured with standard MDR
treatment regimens (6).
Africa accounts for about one-quarter of the world’s TB cases, but few countries in
the region have detailed data on TB management and the prevalence of MDR cases (7).
Gabon is a country in Central Africa with about 1.7 million inhabitants, half of whom live
in the capital, Libreville. The World Health Organization (WHO) estimated that in 2014,
Gabon had an annual incidence of 393 to 497 cases, with an accompanying mortality
rate of 56 to 93 TB deaths per 100,000 inhabitants, making it one of the 10 highest-
incidence countries (7). Between 8 and 11% of Gabonese TB patients are suspected of
having MDR-TB (9), and a recent report from Lambaréné, Gabon, found that 42% of
adult and 16% of pediatric TB patients were coinfected with the human immunodeﬁ-
ciency virus (HIV) (10).
The high incidence of TB cases and TB mortality reﬂects the deﬁciencies in Gabon’s
TB control program (11–13). A survey in 2006 found that only 55% of patients, whose
strains were not routinely tested for drug resistance, completed the standard ﬁrst-line
drug regimen, and a more recent study found only 53% treatment success (7, 10–12).
There is no public health laboratory in Gabon with the ability to perform phenotypic
drug susceptibility testing (DST) (5), and MDR drug regimens are not administered with
standardized protocols in most of the country. However, a WHO-approved MDR
treatment program is currently being implemented, and therefore, identiﬁcation of
MDR-TB patients to receive this treatment has become a priority. The GeneXpert
MTB/RIF assay (Xpert assay; Cepheid, Sunnyvale, CA, USA), was recently introduced into
the country and can rapidly analyze sputum samples to detect the presence of
Mycobacterium tuberculosis bacilli, as well as mutations associated with resistance to
rifampin (RIFr), a marker for MDR-TB (14, 15). The Xpert assay does not, however, detect
the mutations associated with the additional drug resistance that deﬁnes XDR-TB.
We report here a novel method, not requiring cultures or a biosafe infrastructure,
that can detect resistance to drugs other than rifampin. The method ﬁrst employs the
Xpert assay to detect the presence of M. tuberculosis bacilli and RIFr; it then uses the
remainder of the sputum samples prepared for the Xpert assay in PCRs to identify
mutations associated with resistance to additional drugs as well as to deﬁne the lineage
of circulating TB strains. This strategy was used to proﬁle the nature and extent of drug
resistance in Libreville, Gabon.
RESULTS
Use of Xpert remnants for ampliﬁcation and sequencing to ﬁnd mutations
conferring resistance to ﬁrst- and second-line drugs. Of the 130 samples run on the
Xpert instrument, 1 gave a no-result signal, 1 gave an error signal, 1 was positive for M.
tuberculosis but indeterminate for RIFr, and M. tuberculosis was not detected in 3.
Among the remaining 124 Xpert samples, RIFr was detected in 21 (17%), of which 12
were mutated at RpoB amino acid residue 531 or 533, and 9 were mutated at RpoB
residue 516 or 522 (Table 1; Fig. 1).
We then wanted to determine whether the leftover sputa processed in the Xpert
assay could be used with other tests to obtain information on additional drug resis-
tance. The Hain GenoType MTBDRplus assay is a line probe assay that detects rifampin
resistance-associated mutations in rpoB, as well as mutations in katG (16) and inhA (17)
that are associated with resistance to isoniazid (INH). The Hain assay was performed
using Xpert-processed leftovers in order to conﬁrm the Xpert rpoB results and to
identify strains that were also INH resistant, thus conﬁrming them as MDR-TB (Table 1).
The Hain test found rpoB mutations in 19/21 samples that were RIFr by the Xpert assay
and also detected the KatG S315T substitution in 14/21 samples and the C ¡ T
mutation at position 15 in the inhA promoter in 8 samples, with GAB-180 and
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GAB-002 showing both katG and inhA mutations. In one of the two rpoB-discordant
samples (GAB-059), where the Hain test did not conﬁrm the presence of an rpoB
mutation found by the Xpert assay, the Hain test detected a mixed KatG proﬁle with
positive results for both the wild-type (WT) sequence and the S315T substitution,
suggesting that the sample might have contained a mixed population of two strains of
M. tuberculosis. In that case, the rpoB codon 516 mutation detected by the Xpert assay
could have been hidden in the Hain test by the presence of a WT rpoB sequence. In the
other discordant strain (GAB-191), the RIF resistance mutation detected by the Xpert
assay was not found with the Hain test, but because there was no hybridization to the
M. tuberculosis complex-speciﬁc (TUB) control band, the Hain test for this sample was
not valid.
To conﬁrm which strains were MDR, the Xpert leftovers were used in PCRs to amplify
the rpoB, katG, and inhA genes for DNA sequencing (Fig. 1). Readable sequences were
obtained from 70/124 samples (56%) for rpoB, of which 12 had mutations; from 110/124
samples (89%) for katG, of which 10 had mutations; and from 87/124 (67%) samples for
inhA, of which 6 had mutations. The 12 mutated rpoB sequences contained the same
mutations found with the Xpert and Hain tests (Table 1), except that for sample
GAB-076, the Xpert assay detected the codon 522 mutation while the Hain test
detected the codon 516 mutation, but sequencing showed that both mutations were
present. Unfortunately, sequencing of the rpoB gene was not successful for either of the
two samples where the Hain test did not conﬁrm the Xpert results (GAB-059 and
GAB-191). Among the 21 samples found to be RIFr by the Xpert assay, readable katG
sequences were obtained from 18, of which 10 had mutations resulting in the S315T
substitution, and readable inhA sequences were obtained from 19, of which 6 carried
the C¡ T mutation at position15 in the promoter. Despite repeated attempts, it was
not possible to amplify the rpoB gene from 9 samples, or the katG or inhA gene from
3 or 2 samples, respectively.
Most of the sequences yielded the same results found by the Hain test, but a few
were discordant. For two samples (GAB-002 and -180), the Hain test detected the C¡
T mutation at position 15 in the inhA promoter, which was not present in the
FIG 1 Flow chart showing the processing of the 159 sputum samples.
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sequences, but katG mutations were detected in these samples by both the Hain test
and sequencing, making them MDR. Sample GAB-010 was WT for both katG and inhA
by the Hain test but showed the C¡ T mutation at position 15 in the inhA promoter
by sequencing and was therefore classiﬁed as MDR.
Based on sequencing results or a Hain test without a discordant sequence, 18 of the
21 samples (86%) determined to be RIFr by the Xpert assay would be classiﬁed as MDR.
Results for the remaining three samples were as follows. For GAB-017, the Hain test
found a KatG S315T substitution, but the katG sequence was WT. For GAB-191, the Hain
test found the inhA promoter mutation, but the absence of a positive control invali-
dated the Hain test, and no inhA sequence was available. For GAB-059, the Hain test did
not detect an rpoB mutation and showed both mutated and WT katG sequences,
suggesting the possible presence of two strains, one WT and one MDR with rpoB and
katG mutations.
To detect additional antibiotic resistance in the 21 samples determined to be RIFr by
the Xpert assay, we ampliﬁed and sequenced the pncA, gyrA, rrs, and rpsL genes for
detection of mutations associated with resistance to pyrazinamide (PZA), ﬂuoroquino-
lones, the injectable antibiotics, and streptomycin, respectively. Readable sequences
were obtained for pncA in 17/21 (81%) samples, of which 4 (24%) carried mutations
(Table 1; Fig. 1). For the gyrA gene, 20/21 (95%) samples yielded readable sequences,
of which 1 (5%) was mutated. The rrs gene was ampliﬁed and sequenced from the only
three samples that could contain XDR-TB: the sample with the gyrA mutation, the
sample for which sequencing of gyrA was unsuccessful, and a sample from a patient
who had received 7 months of treatment with streptomycin (SM). All three were WT for
the rrs gene, showing that there were no XDR-TB cases. The rpsL gene was sequenced
from the samples of two patients: the patient treated with SM (GAB-173) had a WT rpsL
sequence; but the sample with the gyrA mutation (GAB-002) also had a mutation
causing a K43R substitution in RpsL, making this MDR-FQr sample also SMr.
Epidemiology of MDR-TB patients. Epidemiological data for MDR-TB patients are
shown in Table 2. Of the 18 patients conﬁrmed to have MDR-TB strains, 9 were male
and 9 were female. The mean age was 32 years (range, 18 to 54), and 2 patients were
non-Gabonese. Of the 8 patients who had been treated with ﬁrst-line drugs previously,
6 (75%) had samples that were MDR. One of these 6 patients also had mutations
associated with resistance to FQ and SM, and 2 others had mutations associated with
resistance to PZA. Of the 116 individuals with new TB cases, 12 (10.3%) had strains that
were MDR. Of these 12, 6 (50%) had not started TB treatment when the samples were
taken. One of their strains had a pncA mutation. The remaining 6 individuals with new
MDR-TB cases had begun ﬁrst-line treatment 2, 3, 4 (2 patients), 6, or 8 months prior to
the time the samples were obtained.
Molecular epidemiology of MDR strains. Spoligotypes were obtained for all
124 samples tested by the Xpert assay, as well as for the 29 samples with volume
insufﬁcient for the Xpert assay and the 6 samples for which Xpert analysis was
unsuccessful (Fig. 1). The spoligotypes of two strains grouped with Mycobacterium
africanum West African 1. The most frequent spoligotyping international type (SIT) was
SIT61, found in 42 isolates (Table 3), but none of these were RIFr by any method used.
In contrast, RIFr was found in 5 of 5 ST1, 3 of 16 SIT50, 3 of 6 SIT1196, 2 of 6 SIT370, 3
of 6 SIT2697, 1 of 2 SIT1580, 1 of 6 SIT53, and 1 of the 17 orphan isolates (Table 2). The
single sample with SIT260, which, like ST1, belongs to the Beijing family, was also MDR
and, additionally, FQr and SMr.
The standard mycobacterial interspersed repetitive-unit–variable-number tandem-
repeat (MIRU-VNTR) loci are poorly discriminatory for Beijing strains, so in order to
determine whether the ﬁve SIT1 Beijing MDR strains belonged to the same genotype,
they were analyzed with 4 VNTR systems (VNTR systems 1982, 3232, 3820, and 4120)
reported to be hypervariable for Beijing strains (18, 19). VNTR systems 1982, 3820, and
4120 yielded identical bands for the ﬁve SIT1 Beijing MDR samples (see Fig. S1 in the
supplemental material), suggesting that they all belonged to the same genotype.
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Ampliﬁcation with primers for system 3232 yielded several bands per sample and was
considered uninterpretable. Sequencing of the Rv2629 gene showed that all ﬁve strains
had the 191C genotype, described as a marker for the Beijing-W clade, cluster group 2
(20).
DISCUSSION
The Xpert technology has improved TB diagnosis and can rapidly detect RIFr, which,
as conﬁrmed in this study, is a reliable indicator of MDR-TB (21). However, most
methods for detecting resistance to antibiotics other than rifampin require culturing of
the specimen. Cultures on solid media take more than 2 weeks to turn positive, while
cultures in liquid media can turn positive in 7 to 10 days (22) but pose a greater
biosafety hazard. The Hain MTBDRplus test can be performed directly on sputum
specimens but detects resistance to RIF and INH only. Ampliﬁcation and sequencing of
Xpert leftovers, the alternative method proposed here, yielded readable inhA se-
quences for 19, and readable katG sequences for 18, of the 21 strains determined to be
RIFr by the Xpert assay. This method conﬁrmed that 18/21 strains were unequivocally
MDR. In four instances, the sequence was discordant with the Hain test result (GAB-002,
-0180, -010, and -017), but two of these samples (GAB-002 and 180) were nonetheless
deﬁned as MDR because both sequencing and the Hain test detected substitutions at
KatG residue 315. The other two had conﬁrmed rpoB mutations and a mutation
associated with INH resistance detected by only one technique, but for the sake of
caution, these should probably be regarded as MDR despite the discordant results. The
rpoB discrepancy for GAB-059, together with the presence of signals for both WT and
mutated katG, suggests a mixed infection with both sensitive and resistant bacilli.
Testing for FQ resistance in MDR strains is critical, because treatment failures with
FQ-containing MDR regimens are more likely when the strain is FQr, although MDR
strains with particular gyrAmutations may be cured with higher FQ doses (23). The Hain
MTBDRsl test can detect resistance to FQ and injectable antibiotics, and a new version,
which appeared after the present study was completed, can be used directly with
sputum specimens (24). It might be worthwhile to compare the performance of this test
on Xpert leftovers with its results when it is used directly on sputa.
Our alternative method for detecting XDR-TB, using the leftovers from sputa pro-
cessed for the Xpert assay to amplify and sequence the gyrA and rrs genes, is easy,
quick, and relatively inexpensive. The sequencing can be done by a commercial service,
and if the specimens are processed rapidly and promptly sent to be sequenced, the
results could be available by Internet within about 7 days after the sputum specimen
TABLE 3 Clustered spoligotypesa
SIT Clade
No. of isolates
(% of total) Spoligotype Octal
61 LAM10-CAM 42 (26.42) ▫▫▫▫▫▫▫ 777777743760771
50 H3 16 (10.1) ▫▫▫▫▫ 777777777720771
53 T1 6 (3.8) ▫▫▫▫ 777777777760771
54 MANU2 6 (3.8) ▫▫ 777777777763771
370 T1 6 (3.8) ▫▫▫▫▫▫▫▫ 777777747760471
1196 6 (3.8) ▫▫▫ 777777777761771
2697 MANU2 6 (3.8) ▫▫▫▫▫ 777777743763771
1 Beijing 5 (3.1) ▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫ 000000000003771
42 LAM9 4 (2.5) ▫▫▫▫▫▫▫▫ 777777607760771
523 MANU_ancestor 4 (2.5)  777777777777771
237 3 (1.9) ▫▫▫▫▫▫▫▫▫▫▫▫▫ 777777777700000
378 T1 3 (1.9) ▫▫▫▫▫▫ 777777667760771
2298 T1 3 (1.9) ▫▫▫▫▫▫▫ 777777647760771
176 LAM6 2 (1.3) ▫▫▫▫▫▫▫▫▫▫ 777737607560771
373 T1 2 (1.3) ▫▫▫▫▫ 777777767760771
741 H3 2 (1.3) ▫▫▫▫▫▫ 777777757720771
1580 T1 2 (1.3) ▫▫▫▫▫▫ 777777747760771
1690 MANU2 2 (1.3) ▫▫▫ 777777777762771
aOf 159 total isolates, 120 (75.5%) belonged to clustered spoligotypes; 22 (13.8%) had unique SITs, and 17 (10.7%) were orphan strains.
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is obtained. Although ampliﬁcation of the rpoB gene was successful for only 12 of 21
samples, it is unlikely that this low success rate was due to inhibitors in the stored Xpert
leftovers, because readable sequences were obtained from 18/21 samples for katG,
19/21 samples for inhA, and 20/21 samples with gyrA. Perhaps the success rate with
rpoB could be improved by optimizing the primers. The success rates of sequencing
and the Hain test were roughly the same for sputa with 1, 2, or 3 positivity but
were lower for sputa with fewer than 1 bacilli on microscopy and would probably be
lower still for smear-negative specimens in which the Xpert assay detects M. tubercu-
losis and RIFr.
Xpert leftovers were also used for molecular epidemiology studies with both
spoligotyping and MIRU-VNTR typing. Spoligotyping with the Luminex format showed
that most of the MDR strains belonged to spoligotypes that were also present in
non-MDR strains, but surprisingly, there were no MDR isolates with the most frequent
spoligotype, SIT61, which was seen in 26% of all isolates examined (42/159). An
alarming ﬁnding was that 6 of the 18 conﬁrmed MDR strains belonged to SIT1 or
SIT260, genotypes of the Beijing family that has been associated with many MDR-TB
outbreaks (25, 26). Because MIRU-VNTR typing, even with 24 loci, lacks discriminatory
power for the Beijing family, we used VNTR loci reported to be hypervariable in the
Beijing lineage, which conﬁrmed that the ﬁve SIT1 strains apparently belonged to the
same genotype (18, 19). SIT1 was found only in these ﬁve MDR strains, and SIT260 was
found only in one strain that was MDR, FQr, and SMr. This suggests that while most of
the MDR strains could have developed drug resistance within Gabon, the SIT1 strains
and the SIT260 strain may have been MDR when they were introduced into Libreville.
The origin of these strains is a mystery, since reports from neighboring countries
suggest that Beijing strains are not common in the region, and those found were
generally not MDR (27–29). Follow-up studies are in progress to determine the extent
and epidemiology of the apparent SIT1 MDR outbreak strain and to see if the MDR, FQr,
SMr SIT260 Beijing strain is also spreading.
The strategy employed in this study provided important information on the urgent
tuberculosis problem in Gabon, without the need for cultures or biohazard facilities.
Because only 124 strains were examined in this study, and the sample was not
representative of the entire country, the exact percentages of MDR-TB we found, 10%
of new cases and 75% (6/8) of previously treated cases, may not accurately represent
the situation for all of Gabon, but these high rates are nevertheless ominous and are
likely attributable to the low success rates (only 53 to 55%) reported for ﬁrst-line
therapy in Gabon (10).
This method could be used to efﬁciently provide information on drug resistance and
molecular epidemiology in other low-resource countries and can likely be used with
any molecular test based on the ampliﬁcation of speciﬁc genes or loci (30). Methods for
phenotypic drug sensitivity testing rely on cultures and require a biosafe infrastructure
to reduce the biohazards inherent in the manipulation of clinical samples, and heat
inactivation of bacteria can generate aerosol risks. In contrast, the bacilli in samples
processed for the Xpert assay are no longer viable (31), so they can be used in PCRs
without any special infrastructure.
Whole-genome sequencing (WGS) has been proposed as a more-comprehensive
and safer alternative to phenotypic drug testing and molecular epidemiology (32, 33).
With advances in technology and cost reductions, WGS performed directly on clinical
samples suspected to be MDR or XDR could eventually be cost-effective, even in
low-resource settings. In a possible future algorithm, Xpert leftovers of RIFr samples
could be sent for WGS to determine the full resistance proﬁle, but this would require
better sequencing technology and improved methods for isolating M. tuberculosis DNA
from clinical specimens (34, 35). The strategy used in this study could represent an
efﬁcient interim solution for ﬁnding mutations associated with resistance to second-
and third-line drugs, especially in settings where phenotypic drug sensitivity testing is
not possible, and also for basic or retrospective molecular epidemiology.
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MATERIALS AND METHODS
Specimens. Between October 2014 and February 2015, 159 morning sputum samples were collected
from 159 microscopy-positive patients who either were newly diagnosed with TB or were not cured after
two courses of standard ﬁrst-line therapy. Some patients had also received streptomycin (SM). The
patients presented to one of the three main TB diagnostic laboratories in Libreville, the capital of Gabon:
Nkembo Respiratory Hospital (124 samples), the National Public Health Laboratory (LNSP) (31 samples),
and the Melen regional hospital (4 samples). The bacilli were seen in all samples after Ziehl-Neelsen
staining and were scored as /, 1, 2, or 3 (36).
The Ethics Committee of the Gabon LNSP approved the study (Décision 23022015-1). It was
undertaken in the context of a research agreement between the Institut Pasteur of Paris, France, and the
Government of Gabon. After a written or oral explanation, patients signed an informed consent to allow
the use of their sputa in the study and to provide sociodemographic data and information on previous
TB treatment. All sputum samples were transported to the National Public Health Laboratory and were
processed for the Xpert assay.
Before the addition of the Xpert diluent, 29 sputum samples, 28 from new cases and 1 from a
previously treated patient, had less than the 1-ml volume considered to be the minimum required for the
Xpert assay (15). These samples were processed and, though not assayed with the Xpert test (Fig. 1), were
used in PCRs for spoligotyping. After the speciﬁed volumes of the 130 processed sputum samples were
run on the Xpert system, 375 l of each of the leftover diluted samples was individually placed in a 50-ml
tube containing 25 ml of autoclaved phosphate buffer (Na2HPO4·2H2O and KH2PO4 at 0.067 M [pH 6.8])
to neutralize the alkaline pH of the Xpert leftover to pH 7.0. After centrifugation at 4,500 rpm for 15 min,
the pellets were resuspended in 100 l 1 TE (10 mM Tris-HCl, 1 mM disodium EDTA [pH 8]) and were
transferred to a microtube. The microtube was heated at 90°C for 30 min in a water bath and was frozen
at 40°C for 1 h. After thawing, the lysate was centrifuged at 8,000 rpm for 5 min, and the supernatant
was transferred to a new microtube and was stored at 40°C until it was sent to the Unité de Génétique
Mycobacterienne at the Institut Pasteur in Paris, France, where the rest of the studies were performed.
The 29 samples not run on the Xpert system were similarly processed.
Detection of drug resistance mutations. The processing of the samples is shown in Fig. 1. PCR was
performed with primers targeting rpoB, katG, inhA, pncA, gyrA, rrs, and rpsL (Table 4) to detect mutations
conferring resistance to RIF, isoniazid (INH), pyrazinamide (PZA), the ﬂuoroquinolones (FQ), amikacin
(AMK), kanamycin (KAN), capreomycin (CPN), and SM (Table 4) (37–39). The rpoB, katG, inhA, pncA, gyrA,
and rpsL genes were ampliﬁed separately in 50-l reaction mixtures containing 1 NH4 buffer (Bioline),
10% dimethyl sulfoxide (DMSO), 1.5 mM MgCl2, 0.3 M each primer, 200 M deoxynucleoside triphos-
phates (dNTP), 1 U BioTaq DNA polymerase (Bioline), and 5 l of the Xpert sample remnant diluted 1:10
in water. The thermocycler program was as follows: 95°C for 5 min; 45 cycles of 95°C for 1 min, the
hybridization temperature (Table 4) for 1 min, and 72°C for 1 min; and a ﬁnal extension at 72°C for 7 min.
The rrs gene was ampliﬁed in a 30-l reaction mixture containing 1 GC buffer (TaKaRa), 400 M dNTP,
0.4 M each primer, 1 U TaKaRa LA Taq (TaKaRa Bio Inc., Japan) and 5 l of the Xpert sample remnant
diluted 1:10 in water. The ampliﬁcation program was as follows: 94°C for 5 min; 35 cycles of 94°C for 30
s, 59°C for 30 s, and 72°C for 2 min; and a ﬁnal extension at 72°C for 5 min. Ten microliters of each PCR
product was electrophoresed on a 1% agarose gel to verify the ampliﬁcation. The PCR products were
sequenced with the forward and reverse ampliﬁcation primers (Cochin Sequencing Platform, Paris,
France), and the sequencing results were aligned to the respective wild-type (WT) genes of M. tubercu-
losis H37Rv using Geneious (v9.04), MEGA (v6.06), or BLAST (www.ncbi.nlm.nih.gov). For all strains
without readable rpoB sequences and all strains that were RIFr by the Xpert assay, the Hain GenoType
MTBDRplus assay, v2.0 (Hain Lifescience, Nehren, Germany), was used to detect mutations in rpoB (31),
katG, and inhA (40) according to the manufacturer’s protocol, using 5 l of the undiluted Xpert sample
remnant.
TABLE 4 Primers used to amplify and sequence the Mycobacterium tuberculosis genes associated with resistance to antibiotics
Gene Antibiotic Primer name Primer sequence (5=–3=)
Hybridization
temp (°C)
Product
size (bp)
rpoB Rifampin TR1 TACGGTCGGCGAGCTGATCC 53 411
TR2 TACGG CGTTTCGATGAACC
katG Isoniazid katG1 TGGCCGCGGCGGTCGACATT 60 330
katG2 CCAGCAGGGCTCTTCGTCAG
inhA Isoniazid inhA promo-1 CCTCGCTGCCCAGAAAGGGA 60 248
inhA promo-2 ATCCCCCGGTTTCCTCCGGT
pncA Pyrazinamide pncA1 ATCGCGATGGAACGTGATA 60 950
pncA2 CTGTCACCGGACGGATTTG
gyrA Fluoroquinolones gyrA-F GATGACAGACACGACGTTGC 55 398
gyrA-R GGGCTTCGGTGTACCTCAT
gyrB Fluoroquinolones gyrB-F CCACCGACATCGGTGGATT 54 427
gyrB-R CTGCCACTTGAGTTTGTACA
rrs Aminoglycosides
(capreomycin)
rrs-F AAACCTCTTTCACCATCGAC 59 1,329
rrs-R GTATCCATTGATGCTCGC
rpsL Streptomycin rpsLfw GGCCGACAAACAGAACGT 51 501
rpsLrev GTTCACCAACTGGGTGAC
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Genotyping. Spoligotyping (41, 42) was performed with 43 spacer probes coupled to MagPlex
microspheres using the Luminex MagPix instrument (Luminex Corporation, Austin, TX, USA) and TB-SPOL
Beamedex reagents (Beamedex SAS, Orsay, France). The spoligotyping PCR was carried out with 1
MasterMix (Applied Biological Materials Inc., Richmond, BC, Canada), containing the reaction buffer, 1 U
Taq polymerase, 1.5 mM MgCl2, 0.2 mM dNTPs, with 0.6 M each primer, and 5 l of the Xpert sample
remnant diluted 1:10 in water, in a 30-l ﬁnal volume. The ampliﬁcation program was as follows: 95°C
for 5 min; 45 cycles of 95°C for 1 min, 55°C for 1 min, and 72°C for 30 s; and a ﬁnal extension of 72°C for
7 min. The spoligotyping patterns obtained were sent to the SITVIT Web database (http://www.pasteur
-guadeloupe.fr:8081/SITVIT_ONLINE/description.jsp) for identiﬁcation of the spoligotype international
types.
MIRU-VNTR typing. Typing with four MIRU-VNTR systems (systems 1982, 3232, 3820, and 4120)
reported to be hypervariable in strains of the Beijing lineage was performed with the primers described
previously (18, 19) in a 50-l ﬁnal volume containing 1 PCR buffer, 1 Q-Solution, 500 nM dNTP, 1.5
mM MgCl2, 400 M each primer, 1 U HotStarTaq DNA polymerase (Qiagen), and 5 l of the Xpert sample
remnant diluted 1:10 in water. The PCR parameters were as follows: 95°C for 15 min; 45 cycles of 94°C
for 1 min, 59°C (MIRU 1982, 3820, 4102) or 60°C (MIRU 3232) for 1 min, and 72°C for 1.5 min; and a ﬁnal
extension of 72°C for 10 min. Eight microliters of each ampliﬁed PCR product was electrophoresed on a
1% agarose gel for 60 min at 160 V.
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